Longitudinal Performance of Epi proColon (PERT)
Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)
Sponsor: Epigenomics, Inc
Listed as NCT03218423, this observational or N/A phase trial focuses on Colorectal Cancer and Colorectal Neoplasms and remains ongoing. Sponsored by Epigenomics, Inc, it has been updated 15 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Feb 2024 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2020 — Apr 2020 [monthly]
Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Recruiting
-
Jul 2019 — Jan 2020 [monthly]
Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
-
Dec 2017 — Mar 2018 [monthly]
Recruiting NA
-
Sep 2017 — Dec 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Epigenomics, Inc
For direct contact, visit the study record on ClinicalTrials.gov .